𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer

✍ Scribed by Rigas, A C; Robson, C N; Curtin, N J

Book ID
110072580
Publisher
Nature Publishing Group
Year
2007
Tongue
English
Weight
202 KB
Volume
26
Category
Article
ISSN
0950-9232

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A new prostate cancer therapeutic approa
A new prostate cancer therapeutic approach: Combination of androgen ablation with COX-2 inhibitor
✍ Yi Cai; Yi-Fen Lee; Gonghui Li; Su Liu; Bo-Ying Bao; Jiaoti Huang; Cheng-Lung Hs πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 French βš– 410 KB

## Abstract Prostate cancer is initially responsive to hormonal therapy, but cancers inevitably progress in an androgen‐independent fashion with virtually all tumors evolving into more aggressive androgen refractory disease. Immunohistological comparisons of cyclooxygenase 2 (COX‐2) expressions in

ERK inhibitor PD98059 enhances docetaxel
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells
✍ Stanislav Zelivianski; Matthew Spellman; Mark Kellerman; Vladimir Kakitelashvill πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 390 KB

## Abstract Anticancer drugs docetaxel and vinorelbine suppress cell growth by altering microtubule assembly and activating the proapoptotic signal pathway. Vinorelbine and docetaxel have been approved for treating several advanced cancers. However, their efficacy in the management of advanced horm